The economics of diseases and cures /Randall Waechter, PhD, Associate Director of Research, Assistant Dean School of Graduate Studies, and Associate Professor School of Medicine, St. George's University, West Indies, editor.
- 1 online resource.
- Economic Issues, Problems and Perspectives Ser. .
Includes bibliographies and index.
Intro -- Contents -- Foreword -- Acknowledgments -- List of Acronyms -- Section A. Background and Measures -- Chapter 1 -- The Economics of Diseases and Cures -- Different Levels of Cures: Functional vs. Definitive -- Measuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy -- The Diffusion of Cures -- The Value of Case Studies -- References -- Chapter 2 -- Tools and Assumptions -- Data Sources -- Timelines -- Disease Categorization -- Cure Categorization -- Measures used to Assess the Value of Cures -- Years of Potential Life Lost (YPLL) -- Quality-Adjusted Life Years (QALY) Disability-Adjusted Life Years (DALY) -- Cure Impact -- Calculation Assumptions -- References -- Section B. Infectious Diseases -- Chapter 3 -- Acquired Immunodeficiency Syndrome (AIDS/HIV) -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed and At-Risk -- Disease Impact -- Years of Potential Life Lost (YPLL) -- Disease Impact -- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Future Cure Obstacles Research Development and Treatment Costs -- HIV Cures: Anti-Retroviral Therapy (ART) -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science: Future Obstacles -- Number of Patients Currently Being Treatment -- Number of Patients Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment Using ART per Patient -- Cost of Lifetime Treatment Using ART -- Economic Impact -- Value of Life Added -- HIV Cures -- Vaccination Cure Category -- Cure History -- Cure Science/Cure Obstacles -- Phase I Trials -- Phase II Trials -- Phase III Trials -- References -- Chapter 4 -- Influenza -- Disease Category -- Disease Description, Diagnosis, and Background -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed/At-Risk -- Disease Impact -- Years of Potential Life Lost (YPLL) -- Disease Impact -- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Research, Development and Treatment Costs -- Influenza Cures: Vaccinations -- Cure Category Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated -- Number of People Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-adjusted Life Years (DALY/QALY) -- Average Annual Total/Lifetime Cost of Vaccinations -- Economic Impact -- Value of Life Added -- Economic Impact -- Value of Reduction in DALYs/Increase in QALYs -- Influenza Cures: Antivirals -- Cure Category -- Cure Identification/Description
"This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"--